

THE TOP 10 MEDICATIONS AND THEIR OCULAR SIDE EFFECTS

Blair Lonsberry, MS, OD, MEd., FAAO
Professor of Optometry
Pacific University College of Optometry
blonsberry@pacificu.edu

1

Disclosures:

- Sun Pharmaceuticals: speakers bureau,
- Avellino: advisory board,
- Dompe: advisory board,
- RVL Pharmaceuticals: advisory board

2

Agenda

- Review of the most common systemic medications and their uses and associated ocular side effects:
 - Hydroxychloroquine (Plaquenil)
 - Tetracyclines
 - Amiodarone
 - Antidepressants
 - Steroids
 - Tamoxifen
 - Anti-histamines
 - Flomax
 - Topemax
 - Viagra/Cialis

3

What Factors Increase the Risk – Product Specific Variables

- **Amount of Drug Administered**
 - All medications have potential for toxicity if given in excessive amounts.
 - Long term use of therapeutic doses over time increase the risk of toxicity.
- **Nature of the Drug**
 - Ease of absorption into systemic circulation.
 - Ability to penetrate the blood-brain, blood-aqueous, and blood-retinal barriers.
 - Absorption by ocular tissues such as Melanin.
- **Route of Administration**
 - Highest levels of adverse effects have been seen with oral administration (over inhaled, intranasal, etc.)

4

What Factors Increase the Risk – Patient Specific Risks

- **Pathophysiologic Variables**
 - Liver and Kidney Function
- **Age and Sex**
 - More common in the very young or the very old.
 - More adverse drug reactions are reported in women than in men.
- **History of Allergy to Drugs**
 - Adverse reactions are always more likely in a patient who has had a history of previous trouble.
- **Individual Idiosyncrasy**
 - Factors such as enzymatic differences, muscle mass, etc.
 - Altered tissue responsiveness to a medication is likely hereditary.

5

What Factors Increase the Risk?

- Drug Interactions
 - ▣ Incidence of ADR's is directly related to the number of drugs administered.
 - ▣ Always important to specifically ask about social habits, supplements, etc.



6

Antimalarials

- hydroxychloroquine or Plaquenil
- hydroxychloroquine more common and less toxic than more effective chloroquine
- Common medication used by patient's who are suffering from rheumatoid arthritis
- usual dose is 200-400 mg/d @night with onset of action after a period of 2-4 months
- Primarily used to help manage pain and increase mobility, has a mild affect on slowing down joint destruction

7


Treatment and Management: Antimalarial Ocular Complications

- Have affinity for pigmented structures such as iris, choroid and RPE
- Toxic affect on the RPE and photoreceptors leading to rod and cone loss.
- Have slow excretion rate out of body with toxicity and functional loss continuing to occur despite drug discontinuation.

8

Question

Which of the following depicts a retina undergoing hydroxychloroquine toxicity?



ARMD

Macular Hole

OHS

Bull's Eye Maculopathy


9

Treatment and Management: Antimalarial
Ocular Complications

- Toxicity can lead to whorl keratopathy, “bulls eye” maculopathy, retinal vessel attenuation, and optic disc pallor.
- Early stages of maculopathy are seen as mild stippling or mottling and reversible loss of foveal light reflex
- “Classic” maculopathy is in form of a “bulls eye” and is seen in later stages of toxicity
 - this is an irreversible damage to the retina despite discontinuation of medication

10

Treatment and Management: Antimalarials



Bulls Eye Maculopathy

Whorl Keratopathy

11

Fabry Disease

- alpha-galactosidase-A deficiency.
 - insufficient breakdown of lipids, which build up to harmful levels in the eyes, kidneys, autonomic nervous system, and cardiovascular system.
- Fabry disease is one of several lipid storage disorders and the only X-linked lipid storage disease.
- Lipid storage may lead to impaired arterial circulation and increased risk of heart attack or stroke.
 - The heart may also become enlarged and the kidneys may become progressively involved.
- Other signs include decreased sweating, fever, and gastrointestinal difficulties.

12

Revised Recommendations on Screening for Retinopathy

- 2002 recommendations for screening were published by Ophthalmology
- Revised recommendations on screening published in Ophthalmology 2011; 118:415-42
 - Significant changes in light of new data on the prevalence of retinal toxicity and sensitivity of new diagnostic techniques
 - Risk of toxicity after years of use is higher than previously believed
 - Risk of toxicity approaches 1% for patients who exceed 5 years of exposure

13

Revised Recommendations on Screening for Retinopathy

- Amsler grid testing removed as an acceptable screening technique
 - NOT equivalent to threshold VF testing
- Strongly advised that 10-2 VF screening be supplemented with sensitive objective tests such as:
 - Multifocal ERG
 - Spectral domain OCT
 - Fundus autofluorescence
- “Ideal” body weight versus “real weight” recommended for dosing and at <6.5 mg/kg

14


“New” New Recommendations

- **Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy** – Ophthalmology 2016; 123:1386-1394
 - Released March 2016 from American Academy of Ophthalmology
 - revised in light of new information about the prevalence of toxicity, risk factors, fundus distribution, and effectiveness of screening tools.

15

2016 Recommendations

- maximum daily HCQ use of 5.0 mg/kg real weight, which correlates better with risk than ideal weight.
- risk of toxicity is dependent on daily dose and duration of use.
 - at recommended doses:
 - risk of toxicity up to 5 years is under 1%
 - up to 10 years is under 2%
 - rises to almost 20% after 20 years. However, even after 20 years, a patient without toxicity has only a 4% risk of converting in the subsequent year.



16

2016 Recommendations


- High dose and long duration of use are the most significant risks.
 - Other major factors are concomitant renal disease, or use of tamoxifen
- A baseline fundus examination should be performed to rule out preexisting maculopathy.
- Begin annual screening after 5 years for patients on acceptable doses and without major risk factors.

17

2016 Recommendations

- primary screening tests are automated visual fields plus spectral-domain optical coherence tomography (SD OCT)
- most patients of Asian descent will show initial damage in a more peripheral extramacular distribution near the arcades (require a 24-2 as opposed to 10-2 and OCT scans need to be analyzed further out)

18




19

Revised Recommendations on Screening for Retinopathy

- Parafoveal loss of visual sensitivity may appear before changes are seen on fundus evaluation
 - Many instances where retinopathy was unrecognized for years as field changes were dismissed as “non-specific” until the damage was severe
 - 10-2 VF should always be repeated promptly when central or parafoveal changes are observed to determine if they are repeatable
 - Advanced toxicity shows well-developed paracentral scotoma


20

Paracentral Scotomas




21

Normal Retina: VF/OCT/ERG




22

Mild Maculopathy



23

Bull's Eye Maculopathy



24

Major Risk Factors

Table 1. Major Risk Factors for Toxic Retinopathy

Daily dosage	
HCQ	>5.0 mg/kg real weight
CQ	>2.3 mg/kg real weight
Duration of use	>5 Yrs, assuming no other risk factors
Renal disease	Subnormal glomerular filtration rate
Concomitant drugs	Tamoxifen use
Macular disease	May affect screening and susceptibility to HCQ/CQ

CQ = chloroquine; HCQ = hydroxychloroquine.

25

Screening Recommendations

Table 2. Screening Frequency

Baseline Screening	
Fundus examination	within first year of use
Add visual fields and SD OCT	if maculopathy is present
Annual Screening	
Begin after	5 yrs of use
Sooner in the presence of	major risk factors

SD OCT = spectral-domain optical coherence tomography.

26

Tetracyclines

- Drug of choice for Rocky Mountain Spotted Fever, Cholera, Lyme disease, mycoplasma pneumonia, and chlamydial infections.
- Side effects include gastric discomfort, effects on calcified tissues, vestibular problems.
- **Should not be used in children under the age of 8 due to discoloration of teeth.**

27

Tetracyclines

- This group includes:
 - Tetracycline (250mg - 500 mg cap BID-QID) needs to be taken 1 hour before or 2 hours after a meal.
 - Minocycline (100 mg cap BID)
 - Doxycycline (20mg - 100 mg cap or tab BID)
 - In Canada: Apprilon (30 mg doxy + 10 mg slow release doxy)
- Rules of Thumb with Doxy:
 - Do not take before lying down (>2 hours before)
 - Do not take with calcium and avoid antacids
 - Do not take with dairy
 - Do take with food

28

Tetracyclines: Ocular SE

- Systemic use of this group rarely causes serious SE.
- The most commonly reported SE is pseudotumor cerebri associated primarily with tetracycline and minocycline. Increased intracranial pressure is not dose dependent and may occur as early as 4 hours after first taking the drug or after many years of drug use.
- All tetracycline agents are photosensitizers.



29


Antianginal: Amiodarone

- Brand names: Cordarone, Pacerone
- Antiarrhythmic agent used in the treatment of atrial and ventricular tachycardias.
- Systemic adverse SE include: interstitial pulmonary fibrosis, GI intolerance, tremor, ataxia, dizziness, liver toxicity, photosensitivity, muscle weakness etc.
- After long-term use, more than 50% of Px have to discontinue use due to toxic responses.

30

Antianginal: Amiodarone Ocular SE

- corneal microdeposits occur in nearly all Px who are using the drug long-term
 - ▣ epithelial whorl-like pattern similar as seen in chloroquine treatment
 - ▣ horizontal, irregular branching line near the junction of the mid to outer 1/3rd of cornea



31

Antianginal: Amiodarone Ocular SE

- generally visible keratopathy develops in most Px within 6 weeks after drug initiation and reach peak within 3-6 months
- minimal deposition in Px on a dose of 100-200 mg/day though 400 mg or more will have all Px show deposit
- will see regression in 3-7 months after discontinuation
- other complications include:
 - ▣ decreased VA,
 - ▣ color vision defects,
 - ▣ photosensitivity,
 - ▣ dry eyes,
 - ▣ decreased corneal sensation,
 - ▣ optic neuropathy and
 - ▣ pseudotumor.

32

Antidepressants

- Includes:
 - ▣ Tricyclic antidepressant (TCA): amitriptyline, nortriptyline (Elavil, Levate) (inexpensive medication)
 - ▣ Selective serotonin re-uptake inhibitors (SSRI): fluoxetine (Prozac), paroxetine (Paxil), sertraline (Zoloft) (all of these are very expensive medications!)
 - ▣ monoamine oxidase (MAO): isocarboxazid (Marplan)

33


Antidepressants: Summary of Ocular Side Effects

- most of the side effects are transient, reversible, and cause little clinical significance
- most common side effects is blurring of vision which is generally mild and transient (improves with sustained use of medication)
- mydriasis can be a concern in patients with NAG or narrow angles
- diplopia and nystagmus have been reported though generally in patients who are currently using other agents such as lithium or diazepam
- increased symptoms of dry eye

37


Corticosteroids (Glucocorticoids)

- Glucocorticoids promote normal metabolism (e.g. gluconeogenesis, protein catabolism), increase resistance to stress, alter blood cell levels (e.g. decrease eosinophils, basophils, monocytes and lymphocytes), and have anti-inflammatory action.



38

Corticosteroids- Systemic SE




- Systemic administrations can result in:
 - Osteoporosis
 - Increased appetite
 - Emotional disturbances
 - Hypertension
 - Edema
 - Peptic ulcers
 - Increased risk of infection

39

Corticosteroids- Ocular SE

- Systemic use can result in:
 - ▣ PSC cataracts
 - ▣ Increased IOP
 - ▣ Delayed wound healing
 - ▣ Decreased resistance to infection
 - ▣ Visual hallucinations
 - ▣ Subconjunctival/retinal hemes and edema
 - ▣ Papilledema



40

Corticosteroids: Ocular SE

- Race is important as steroid induced glaucoma is more frequent in whites than blacks, and depigmentation from SC injection is more frequent in blacks.
- Steroid IOP responders tend to have more field loss than non-responders, more common in POAG and 1st degree relatives of POAG patients, higher risk in younger children and typically presents 4-6 weeks after initiation of steroid.
- Steroids affect all ocular structures resulting in development of steroid induced glaucoma, PSC cataracts, enhanced HSK infections, decreased wound healing, band keratopathy, etc.

41


Estrogen Receptor Antagonist-Tamoxifen

- Tamoxifen is used in the treatment of breast cancer (normal breast tissue stimulated to grow by estrogens, so estrogen antagonists can result in tumor regression)
- The most common adverse affects include: hot flashes, nausea, and vomiting. Menstrual irregularities and vaginal bleeding can also occur.

42

Estrogen Receptor Antagonist-Tamoxifen-Ocular SE

- Significant visual loss can occur with tamoxifen. Stopping Tx usually prevents further deterioration but may not result in visual recovery.
- Tamoxifen retinopathy characterized by presence of refractile bodies (due to axonal death).
- Additional findings may include CME, macular and peripheral retinal RPE changes, parafoveal hemes and subepithelial corneal deposits.



43


Antihistamines: Ocular SE

- Systemic use of the medications have a weak atropine action that accounts for the pupillary changes. With chronic use, anisocoria, decreased accommodation, and blurred vision can also occur.
- There has also been evidence to demonstrate a decrease in tear production making Px symptomatic for dry eyes and CL intolerance.

44

Tamsulosin (Flomax)

- Used to treat prostate enlargement and improve urinary flow in men (urologists are treating women with this drug).
- The well-known syndrome, intraoperative floppy iris syndrome, used to occur only in men but now has to be a concern for women who may also be taking the medication.
- Even if the drug is discontinued, the patient is at a lifetime risk of more complicated cataract surgery.



45

Topiramate (Topamax)

- Used for the treatment of:
 - ▣ seizures,
 - ▣ epilepsy,
 - ▣ migraine prophylaxis,
 - ▣ bipolar and post-traumatic stress disorders, and neuralgias.
- used off-label to control bingeing and purging, and to promote weight loss in people with eating disorders

46

Topiramate (Topamax) Ocular Side Effects

- include:
 - ▣ acute angle closure glaucoma,
 - ▣ ocular pain,
 - ▣ headache,
 - ▣ hyperemia,
 - ▣ mydriasis,
 - ▣ uveitis,
 - ▣ visual field defects,
 - ▣ acute onset myopia, suprachoroidal effusions,
 - ▣ blepharospasm,
 - ▣ retinal hemorrhage and
 - ▣ scleritis

47

Sildenafil citrate (Viagra) and tadalafil (Cialis)


- Prescribed for men with erectile dysfunction. These drugs divert blood flow away from the head
- They cause two problems:
 - ▣ can cause blue vision, because they interfere with neurotransmission within the retina. That is fortunately not a permanent side effect.



48

Sildenafil citrate (Viagra) and tadalafil (Cialis)


- The other possible side effect is ischemic optic neuropathy.
- The evidence that there is a cause-and-effect relationship is tenuous.



49

Retinoids: Isotretinoin

- Retinoids are analogues of Vitamin A used because of their ability to damage rapidly dividing cells.
- Isotretinoin (Sotret, Claravis, Amnesteem, Generics, Formerly known as Accutane) is the most commonly prescribed Retinoid used in the control of severe acne or various keratinizing dermatoses.
- It was originally developed as a chemotherapy agent.
- MOA: Temporarily suppresses the sebaceous gland activity, altering the surface lipid composition on the skin, and inhibiting keratinization.



50

Isotretinoin

- Very frequent cause of ocular side effects.
- Complications generally begin within 4 weeks of starting the medication, and will resolve approximately 4 weeks following discontinuation.
- Symptoms are dose related.

Table 11. Ocular adverse events reported while treated with isotretinoin.

Visual event	No. of reports
Visual changes	
Blurred vision	473
Photophobia	320
Decreased visual acuity	27
Decreased tolerance for contact lens	26
Conjunctiva	
Xanthema	204
Chemosis	122
Conjunctivitis	102
Activation of herpes simplex virus	9
Keratoconjunctivitis	8
Conjunctival hemorrhage	6
Conjunctival edema	5
Ocular pain/irritation	
Ophthalmic conjunctivitis	229
Subconjunctival hemorrhage	14
Corneal abrasion	11
Foreign body sensation	9
Photophobia	7
Other	
Ischemic optic neuropathy	243
Neurological disorders	
Ocular muscle paresis	109
Ocular pain	22
Ocular hyperemia	22
Ocular irritation	6
Decreased dark adaptation	140
Pharmacologic	
Pharmacologic conjunctivitis	80
Pharmacologic keratitis	20
Visual evoked response	0
Visual field defect	0
Conjunctival edema	2
Conjunctivitis	2
Iritis	2
Exposure	1
Retinopathy	
Retinopathy	12
Other	
Cataract	50
Chalazion	26
Exposure	24
Phlegm	12
Myopia	10
Exotropia	9
Argemone keratitis	8
Ocular pain	17
Ischemia	14
Color vision (decreased)	9
Exotropia	7

51

Isotretinoin

- Major Ocular Side Effect: Alteration of Meibomian Gland Secretions
 - Gland atrophy frequently develops which is beneficial for the treatment of acne, but harmful for the ocular surface.
 - Decreased Volume with Increased Thickness
 - Results in:
 - High levels of tear evaporation
 - Increased Tear Film Osmolarity
 - Ocular Discomfort
- Most Common Ocular Finding in 20-50%:
 - Blepharoconjunctivitis



52

Isotretinoin and Blepharoconjunctivitis


- Severity can vary, but may lead to corneal involvement and blurry vision.
- Nearly all patients will experience difficulty with Contact Lenses.
 - Need to reduce wearing time.
- Treatment is Artificial Tear Supplementation:
 - Which type would you recommend?



53

Retinoids/Isotretinoin

- Intracranial HTN (Pseudotumor Cerebri)
 - Can be caused by Vitamin A itself or the derivatives such as Isotretinoin.
 - Retinoids are one of the two main categories of drugs that result in increased intracranial pressure.
 - Second major drug class is the tetracycline derivatives, especially minocycline.
 - Risk increases if tetracyclines are used in combination with retinoids.



55

Ethambutol

- Bacteriostatic, antimycobacterial medication used in the treatment of tuberculosis.
- Recommended to be given in combination with first line treatment Isoniazid, Rifampin, and Pyridoxine until drug susceptibility has been determined.



56

Ethambutol

- Primary Ocular Manifestation: Retrobulbar Neuritis
 - Two forms resulting from toxicity:
 - Most Common: Central with loss of VA and color vision
 - Less Common: Peripherally with contraction of VF
- Also, can have retinal findings such as ONH swelling, hemes, and macular edema = RARE.
- MOA: Damage to the amacrine and bipolar cells (Not fully understood)
- Earliest finding is often loss of contrast sensitivity, followed by color vision.
 - Isoniazid is also known to cause optic neuritis, but in much less frequent numbers.



57

Ethambutol

- Deterioration will continue even if ethambutol is discontinued.
- Largely affected by dosage:
 - ▣ Recommended levels should not exceed 15 mg/kg daily.
 - Can tolerate higher levels for no longer than 2 months to prevent optic nerve damage.



58
